ReviewDrug design, development and therapy2026
Population Pharmacokinetics and Clinical Application of Vancomycin in Critically Ill Adults: A NONMEM-Based Review.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vancomycin remains an important treatment for severe Gram-positive infections in the intensive care unit (ICU), but critically ill adults show highly variable pharmacokinetics, making conventional dosing unreliable. This review aimed to summarize Nonlinear Mixed-Effects Modeling (NONMEM)-based population pharmacokinetic studies of vancomycin in critically ill adults and identify clinically relevant covariates associated with exposure variability. PubMed, Embase, and Google Scholar were searched from inception to January 2026. Twelve original studies met the inclusion criteria. All focused on adult ICU populations and used nonlinear mixed-effects modeling with NONMEM. One-compartment models were most commonly used, although parameter estimates varied substantially across populations. Typical clearance ranged from 1.19 to 5.15 L/h. Excluding volume estimates that needed to be normalized to actual body weight, reported typical values ranged from 29.2 to 107 L. Covariate analyses consistently identified renal function and body weight as important determinants of clearance, whereas continuous renal replacement therapy (CRRT)/high-volume hemofiltration (HVHF) intensity and residual renal function were particularly relevant in patients receiving extracorporeal support. Mechanical ventilation was retained as a covariate on clearance in some models. Overall, these findings highlight the marked heterogeneity of vancomycin pharmacokinetics in critical illness and support more individualized dosing strategies, ideally combining early therapeutic drug monitoring with model-informed precision dosing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.